Advancing Our Understanding of IVIg in Pediatric Acute-Onset Neuropsychiatric Syndrome

Abstract

Intravenous immunoglobulin (IVIg) is a pooled product containing polyclonal IgG collected from the plasma of thousands of healthy donors. Originally developed as a replacement therapy for patients with humoral immunodeficiencies, IVIg has since been widely adopted in the treatment of several autoimmune and inflammatory conditions, owing to its extensive immunomodulatory and anti-inflammatory effects. IVIg exerts a wide range of actions by influencing multiple components of both the innate and adaptive immune systems. These include modulation of Fcγ receptor expression and function, inhibition of complement activation, neutralization of autoantibodies, regulation of cytokine networks, control of pro-inflammatory monocytes, and regulation of multiple immune cells, also through epigenetic modulation. Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) represents one of the most complex conditions in pediatric neuropsychiatry, involving the basal ganglia and characterized by a broad range of abrupt-onset neuropsychiatric symptoms, irrespective of the underlying infectious trigger. Recent clinical and translational studies indicate that IVIg can attenuate neuropsychiatric symptoms and restore immune balance in children with PANS. Randomized trials have produced variable results. Converging clinical and mechanistic evidence supports the potential therapeutic value of IVIg in selected patients with moderate-to-severe or relapsing disease. In this overview, we examine current data on IVIg use in PANS, emphasizing its immunological rationale, emerging clinical benefits, and the need for biomarker-guided studies to better identify responders and optimize treatment outcomes. 

Keywords

immune-mediated diseases / intravenous immunoglobulin / monocytes / Pediatric Acute-Onset Neuropsychiatric Syndrome

References

[1] Galeotti, C.; Kaveri, S.V.; Bayry, J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int. Immunol. 2017, 29, 491-498.

[2] Gelfand, E.W. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 2012, 367, 2015-2025.

[3] Melamed, I.; Rahman, S.; Pein, H.; et al. IVIG response in pediatric acute-onset neuropsychiatric syndrome correlates with reduction in pro-inflammatory monocytes and neuropsychiatric measures. Front. Immunol. 2024, 15, 1383973.

[4] Masterson, E.E.; Gavin, J.M. Baseline characteristics of children in the International PANS Registry (IPR) Epidemiology Study. BMJ Open 2024, 14, e072743.

[5] Leonardi, L.; Perna, C.; Bernabei, I.; et al. Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS): Immunological Features Underpinning Controversial Entities. Children 2024, 11, 1043.

[6] Marconi, D.; Limpido, L.; Bersani, I.; et al. PANDAS: A possible model for adult OCD pathogenesis. Riv. Psychiatry 2009, 44, 285-298.

[7] Kumar, A.; Williams, M.T.; Chugani, H.T. Evaluation of basal ganglia and thalamic inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection and Tourette syndrome: A positron emission tomographic (PET) study using 11C-[R]-PK11195. J. Child. Neurol. 2015, 30, 749-756.

[8] Zheng, J.; Frankovich, J.; McKenna, E.S.; et al. Association of Pediatric Acute-Onset Neuropsychiatric Syndrome with Microstructural Differences in Brain Regions Detected via Diffusion-Weighted Magnetic Resonance Imaging. JAMA Netw. Open 2020, 3, e204063.

[9] Basta, M.; Dalakas, M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Investig. 1994, 94, 1729-1735.

[10] Mitrevski, M.; Marrapodi, R.; Camponeschi, A.; et al. Intravenous Immunoglobulin and Immunomodulation of B-Cell—In vitro and in vivo Effects. Front. Immunol. 2015, 6, 4.

[11] Lünemann, J.D.; Quast, I.; Dalakas, M.C. Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics. 2016, 13, 34-46.

[12] Negi, V.S.; Elluru, S.; Sibéril, S.; et al. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J. Clin. Immunol. 2007, 27, 233-245.

[13] Rambabu, N.; Alzaid, F.; Anđelković, B.D.; et al. Regulation of immune cell metabolism by therapeutic normal IgG intravenous immunoglobulin. J. Allergy Clin. Immunol. 2025, 156, 418-432.

[14] Danieli, M.G.; Shoenfeld, Y. Expanding the mosaic functions of intravenous Immunoglobulin. J. Allergy Clin. Immunol. 2025, 156, 327-329.

[15] Byary, J.; Ahmed, E.A.; Toscano-Rivero, D.; et al. Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions. J. Allergy Clin. Immunol. Pract. 2023, 11, 1688-1697.

[16] Schwab, I.; Nimmerjahn, F. Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat. Rev. Immunol. 2013, 13, 176-189.

[17] Kaufman, G.N.; Massoud, A.H.; Dembele, M.; et al. Induction of regulatory T cells by intravenous immunoglobulin: A bridge between adaptive and innate immunity. Front. Immunol. 2015, 6, 469.

[18] Buttmann, M.; Kaveri, S.; Hartung, H.P.; Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol. Sci. 2013, 34, 445-457.

[19] Fabricius, R.A.; Sørensen, C.B.; Skov, L.; et al. Cytokine profile of pediatric patients with obsessive-compulsive and/or movement disorder symptoms: A review. Front. Pediatr. 2022, 10, 893815.

[20] Han, V.X.; Nishida, H.; Keating, B.A.; et al. IV Immunoglobulin Is Associated with Epigenetic, Ribosomal, and Immune Changes in Pediatric Acute-Onset Neuropsychiatric Syndrome. Neurol. Neuroimmunol. Neuroinflamm 2025, 12, e200467.

[21] Rodriguez, M.; Miller, D.J.; Lennon, V.A. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996, 46, 538-545.

[22] Gromark, C.; Hesselmark, E.; Djupedal, I.G.; et al. A Two-to-Five Year Follow-Up of a Pediatric Acute-Onset Neuropsychiatric Syndrome Cohort. Child. Psychiatry Hum. Dev. 2022, 53, 354-364.

[23] Eremija, J.; Patel, S.; Rice, S.; Daines, M. Intravenous immunoglobulin treatment improves multiple neuropsychiatric outcomes in patients with pediatric acute-onset neuropsychiatric syndrome. Front. Pediatr. 2023, 16, 1229150.

[24] Costagliola, G.; Cappelli, S.; Consolini, R. Autoimmunity in Primary Immunodeficiency Disorders: An Updated Review on Pathogenic and Clinical Implications. J. Clin. Med. 2021, 10, 4729.

[25] Williams, K.A.; Swedo, S.E.; Farmer, C.A.; et al. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections. J. Am. Acad. Child. Adolesc. Psychiatry 2016, 55, 860-867.e2.

[26] Dailey, M.M.; Colombo, G.M.; Pinciotti, C.M.; et al. Parent perceptions of various treatment approaches for PANS and PANDAS. J. Affect. Disord. 2025, 369, 1215-1222.

[27] Xu, J.; Liu, R.J.; Fahey, S.; et al. Antibodies From Children with PANDAS Bind Specifically to Striatal Cholinergic Interneurons and Alter Their Activity. Am. J. Psychiatry 2021, 178, 48-64.

[28] Cross, A.; Bouboulis, D.; Shimasaki, C.; et al. Case Report: PANDAS and Persistent Lyme Disease With Neuropsychiatric Symptoms: Treatment, Resolution, and Recovery. Front. Psychiatry 2021, 12, 505941.

[29] Johnson, M.; Ehlers, S.; Fernell, E. ; et al. Anti-Inflammatory, Antibacterial and Immunomodulatory Treatment in Children with Symptoms Corresponding to the Research Condition PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome): A Systematic Review. PLoS ONE 2021, 16, e0253844.

[30] Hajjari, P.; Oldmark, M.H.; Fernell, E.; et al. Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): Comprehensive open-label trial in ten children. BMC Psychiatry 2022, 22, 535.

[31] Frankovich, J.; Swedo, S.; Murphy, T.; et al. Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part II—Use of Immunomodulatory Therapies. J. Child. Adolesc. Psychopharmacol. 2017, 27, 574-593.

[32] Efe, A. SARS-CoV-2/COVID-19 associated pediatric acute-onset neuropsychiatric syndrome: A case report of female twin adolescents. Psychiatry Res. Case Rep. 2022, 1, 100074.